Key Dates
None
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for research on mechanisms of inflammasome activation and its link to immune functions in people with HIV and substance use disorders.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in Fall 2022 with an expected application due date in Spring 2023.
This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.
This Notice informs the research community of this new initiative and encourages investigators with expertise and insights into this area of exploring inflammasome and immune functions pertinent to myeloid cells in context of substance use and HIV to begin to consider applying for this new FOA.
In addition, research exploring inflammasome and immune functions pertinent to myeloid cells in context of substance use and HIV will be encouraged..
Among the areas of research encouraged in this initiative are understanding the involvement of myeloid cells regulated inflammasome activation, cross interactions with humoral adaptive immunity, and interplays among myeloid cells and neurons as well as other CNS resident cells that may help identify molecular markers and CNS immune cells associated with HIV-1 infection, latency, or disease progression among substance abuse populations, and identify novel therapies to treat neuroinflammation and immune dysregulation aroused in these processes.
TBD
NIDA intends to commit $4M for FY 23
TBD
TBD
Applications are not being solicited at this time.
Please direct all inquiries to:
Shang-Yi Anne Tsai, Ph.D.
National Institute on Drug Abuse
301-827-5842